Covid-19 DHA 2018.1 sbir phase III medical r & d contract proposal titled: "targeting SPLA2 for treatment of acute respiratory distress syndrome (ards) associated with sars-COV-2" log #19000053
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0066
- Awardee
-
Ophirex, Inc. UEI W452WY5E2JQ9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $9,228,796
Award facts
- Opportunity
-
- HQ003418R1ADB Solicitation number
- Contract value 87% obligated
-
- $9,926,612.36 Current, with exercised options
- $10,571,594.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Medical Command Department of the Army, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Corte Madera, CA 94925, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$644,982 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $697,816 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $9,873,778 |
About this award
The Defense Health Agency awarded a $10.6 million firm fixed-price contract to Ophirex, Inc., a small business located in Corte Madera, California, under the Small Business Innovation Research (SBIR) Phase III program. The contract, awarded June 19, 2020, with an ultimate completion date of September 29, 2023, supports research and development of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor designed to treat acute respiratory distress syndrome (ARDS) associated with SARS-CoV-2. The total small business set-aside designation prioritizes small business participation in this critical medical research effort during the COVID-19 pandemic response.
Ophirex specializes in developing advanced pharmaceutical interventions and operates as a public benefit corporation focused on reducing death and disability through innovative therapeutic solutions. The SBIR Phase III contract represents a continuation of the company's work leveraging its expertise in sPLA2 inhibition technology, which is relevant to treating ARDS given that sPLA2 mediates inflammatory responses implicated in severe COVID-19 disease progression. The Defense Health Agency's investment in this research aligns with broader efforts to identify novel therapeutic approaches for managing severe respiratory complications associated with the novel coronavirus.
Quick answers
Who was awarded contract W81XWH20C0066?
W81XWH20C0066 was awarded to Ophirex, Inc. by Defense Health Agency (Department of Defense) on June 19, 2020.
How much is contract W81XWH20C0066 worth?
The government has obligated $9,228,796 on W81XWH20C0066. Its current value, with exercised options, is $9,926,612. Its potential value, with all options, is $10,571,594.
Which agency awarded contract W81XWH20C0066?
Defense Health Agency (Department of Defense) awarded W81XWH20C0066, with funding from Medical Command (Department of the Army).
Was contract W81XWH20C0066 competed?
The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award